Sensei biotherapeutics to present new preclinical data for sns-103, a conditionally active monoclonal antibody targeting entpdase1 (cd39), at the american association for cancer research (aacr) annual meeting 2023

Boston, march 14, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on sns-103, a conditionally active, monoclonal antibody targeting entpdase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as cd39) at the american association for cancer research (aacr) annual meeting 2023, being held april 14-19, 2023 in orlando, fl.
SNSE Ratings Summary
SNSE Quant Ranking